Phaseline

Targets › IRAK1

IRAK1 (Interleukin-1 receptor-associated kinase 1): drug programs, companies and trials

2 programs from 2 companies in 19 trials: 11 Phase 2, 7 Phase 1, 1 Phase 3; Oncology, Hematology, Immunology; next expected readout Dec 2026.

Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. Involved in Toll-like receptor (TLR) and IL-1R signaling pathways. (UniProt, P51617)

Open in Phaseline: the race on IRAK1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Swedish Orphan BiovitrumPacritinib
Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Activin receptor type-1 inhibitor
JAK2, FLT3, ACVR1, IRAK1Phase 3Primary Myelofibrosis; VEXAS; Myelofibrosis; Acute Myeloid Leukemia …Dec 2026
TheradexPacritinib
Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Activin receptor type-1 inhibitor
JAK2, FLT3, ACVR1, IRAK1Phase 2Leukemia, Myelomonocytic, ChronicJul 2028

Conditions

Primary Myelofibrosis (2) Myelofibrosis (2) VEXAS (1) Acute Myeloid Leukemia (1) T-Cell Neoplasm (1) Myelofibrosis,MF (1) Waldenström Macroglobulinemia (1) Accelerated Phase Myeloproliferative Neoplasm (1) Prostate Cancer (1) KSHV Inflammatory Cytokine Syndrome (KICS) (1) Breast Cancer (1) E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome (1)

Modalities

small molecule (2)

Companies

Swedish Orphan Biovitrum (1) Theradex (1)

Related targets

JAK2 (2) FLT3 (2) ACVR1 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.